If you’ve watched cable news recently, you may have seen a PhRMA commercial. In it, we are introduced to a comically tall hospital executive named “Mark,” who repeatedly urges hospital employees to “markup” the price of drugs and pocket the difference.
It’s a clever gag, but the message is pointed. It suggests that hospitals are exploiting a federal drug discount program to inflate prices and boost their margins while insurers, and ultimately employers and patients, pay more.
Like most political advertising, it simplifies a complicated story by focusing on hospital margins while omitting how the program actually works and why it has expanded. But it draws attention to an obscure federal policy that has quietly grown into one of the most consequential programs in American drug pricing: the 340B Drug Pricing Program. Here’s what it is, and why it has become a flashpoint.
What Is 340B?
Congress created the 340B Drug Pricing Program in 1992 to support a small number of safety net providers. The idea was well-intentioned: hospitals and clinics that treat large numbers of low-income and uninsured patients would be allowed to purchase certain outpatient prescription drugs at steep, mandatory discounts from pharmaceutical manufacturers.
Importantly, the program does not involve a direct federal subsidy. This design choice is crucial for understanding today’s debate. Instead, drug companies must provide these discounts as a condition of participating in Medicare and Medicaid. The design allowed lawmakers to support vulnerable providers without writing new appropriations into the federal budget.
At the time, one could argue that the structure made sense. Medicare Part D did not exist. Medicaid eligibility was more limited. Many seniors and low-income Americans lacked reliable prescription drug coverage. Discounted drug acquisition was intended to expand access. But the health care system of 1992 is not the system we have today.
How Big Has It Become?
Over the past three decades, the 340B program has expanded dramatically. From roughly 50 providers at the outset, now more than half of U.S. hospitals participate. The program grew from roughly $5 billion in discounted purchases in 2010 to $81.4 billion in 2024, with hospitals accounting for 87%.
This growth has been driven both by legislative changes and administrative guidance. Rules allowed hospitals to use outside “contract pharmacies,” and limits on their number were removed. The result: a single contract pharmacy in the mid-1990s grew to roughly 32,000 by 2024. Off-campus outpatient facilities could qualify. The program now spans more than 50,000 covered-entity sites. That growth is central to today’s controversy.
Where Does The “Markup” Come From?
The controversy centers on the spread between what hospitals pay and what they are reimbursed. Hospitals in the 340B program acquire drugs at discounted prices. When those drugs are administered to insured patients, hospitals typically bill Medicare, Medicaid, or private insurers at standard reimbursement rates. The difference between acquisition cost and reimbursement becomes additional revenue.
Federal law does not require hospitals to pass the discount on to patients. For uninsured individuals, some hospitals provide charity care or reduced pricing. But for insured patients — including those covered by commercial plans — reimbursement generally reflects established payment formulas rather than the hospital’s actual acquisition cost. The realized spread is smaller than the gap between list and acquisition cost would suggest, since reimbursement typically runs below list, a point even program critics acknowledge. But it is real, and for high-cost specialty drugs delivered in outpatient settings, it can be substantial. That is the “Mark” the commercial caricatures.
Why This Matters Beyond Drug Pricing
Viewing 340B as just a skirmish between drug companies and hospitals misses the point. Hospitals are among the largest cost centers in the American economy. Hospital spending now accounts for nearly one-third of all U.S. health care expenditures. Commercial insurers routinely pay hospitals prices that are two to three times what Medicare pays for the same services, costs ultimately borne by employers and households.
Unlike drug prices, which are highly visible and salient to patients, hospital prices are often negotiated privately and vary widely across markets. In many regions, a small number of hospital systems dominate local markets and possess significant pricing leverage.
The 340B program operates inside that environment. When hospitals can acquire drugs at discounted prices but bill insurers at standard outpatient rates, the resulting margin becomes another revenue stream.
Crucially, the distribution of those margins is not neutral across providers. Evidence suggests that a disproportionate share of 340B revenue accrues to large nonprofit hospital systems with substantial commercially insured patient bases, precisely because they can apply the discounted acquisition cost to higher private-payment reimbursement rates. By contrast, hospitals that primarily serve Medicaid and uninsured populations generate less margin on a per-patient basis. This raises a subtle but important point: the program’s financial benefits may tilt toward institutions with stronger private-payer mix rather than those most reliant on safety-net funding.
340B is not the primary driver of health care inflation. But it reinforces the financial dynamics of a high-priced hospital sector, helping explain why its rapid growth has attracted scrutiny.
Do Patients Benefit?
Supporters of 340B argue that the additional revenue supports essential services. Hospitals often say they use the funds to offset uncompensated care, expand oncology programs, maintain rural facilities and support community health initiatives. However, a recent review of dozens of studies found 340B increased revenue to hospitals, clinics and pharmacies, but only “mixed evidence” that the funds were used to support care for low-income populations.
Additionally, the program does not require hospitals to document how 340B-generated revenue is spent, nor does it tie discounts directly to individual low-income patients. At the same time, many patients whom the program was originally designed to help now receive prescription drug coverage through Medicaid, Medicare Part D or subsidized plans under the Affordable Care Act.
That evolution raises a legitimate policy question. If low-income patients already receive drug coverage through other programs, what role should 340B play in today’s system? Is it primarily expanding access, or has it become a broader revenue mechanism for participating hospitals? Reasonable people can disagree, but the question is no longer theoretical.
Why Pharma Is Pushing Back
For years, manufacturers treated 340B as a contained cost of doing business. But as hospital participation expanded and health systems consolidated, the scale of discounted purchases increased.
Manufacturers now argue that 340B encourages hospitals to favor higher-priced drugs, since the margin between discounted acquisition cost and reimbursement grows with price. They also contend that the program encourages physician practices to integrate into hospital systems, where drugs can be billed under outpatient hospital payment rules.
Hospitals respond that manufacturers are attempting to undermine a vital support mechanism for safety-net providers. Both sides have economic incentives. Both are acting accordingly.
The Larger Policy Question
Some readers may wonder whether it matters if pharmaceutical companies earn less under 340B. After all, drug manufacturers are profitable firms.
But the central issue is not whether profits are high. It is whether an opaque discount mechanism embedded in hospital reimbursement is the most efficient and transparent way to support vulnerable patients.
Congress could subsidize safety-net care directly and transparently. Instead, 340B operates indirectly. It shifts revenue from taxable manufacturers to nonprofit hospitals without annual budget scoring or clear reporting requirements.
Indirect financing can obscure who ultimately bears the cost. In competitive markets, part of that cost may be passed through in higher launch prices or commercial negotiations. In concentrated hospital markets, it may reinforce existing pricing leverage.
Is 340B a lifeline? A distortion? A transfer mechanism? In practice, it likely contains elements of all three. What is clear is that it has grown far beyond its original design.
What Happens Next?
The political fight is intensifying. Congress has held hearings. States are debating contract pharmacy rules. Manufacturers are testing legal challenges. Hospital associations are mobilizing to protect the program.
Reform proposals range from requiring hospitals to pass discounts directly to patients, to tightening eligibility criteria, to increasing transparency around how funds are used. Others argue that flexibility is precisely what allows the program to support vulnerable communities.
For a program that most Americans have never heard of, 340B now sits at the center of a major policy battle: one that will determine whether support for safety-net care is delivered transparently, or continues through an opaque and rapidly expanding system.
